Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Novo Nordisk, OpenAI partner to integrate AI across drug discovery, manufacturing and corporate operations
Research collaboration, AI/ML, drug discovery, manufacturing, R&D - Read more

J&J raises 2026 revenue guidance to $100.8B after strong Q1 earnings of $24.1B
Monoclonal antibody, oncology, financial, strategic - Read more

J&J touts 1,500 early prescriptions for new psoriasis pill Icotyde as Stelara sales tumble 60%
Oral peptide, autoimmune, revenue impact, competitive - Read more

Most clinical accounting teams spend weeks chasing vendor estimates and updating spreadsheets just to close a single period. There’s a faster way - and you can watch it happen live.

Join Auxilius on April 28th at 2PM ET as we walk through a real, end-to-end period close in real time. You’ll see exactly how leading biopharmas have cut their close cycle while improving accuracy and audit readiness.

Essential for Corporate Controllers, VPs of Finance, and FP&A leaders responsible for clinical trial accounting and close. Save your spot now.

Harbinger Health raises $100M to develop RESOLVE multi-cancer liquid biopsy detection tests
Oncology, liquid biopsy, multi-cancer detection, biomarker discovery, clinical-stage - Read more

Alamar Biosciences files for $159M IPO, protein sequencing and biomarker profiling tools
Protein sequencing, biomarker discovery, medtech, inflammation panel - Read more

Lightcast raises $27M financing to commercialize Envisia single-cell functional analysis platform
Single-cell analysis, life science tools, antibody discovery, oncology, platform technology - Read more

Senhwa Biosciences secures up to NT$500M from GEM, advancing AI-driven drug development
Oncology, AI/ML platform, cancer immunotherapy, clinical-stage, immuno-oncology - Read more

Adcendo raises $75M Series C to advance trio of ADC clinical candidates
Oncology, antibody-drug conjugate, clinical-stage, solid tumors - Read more

Spiral Therapeutics raises $27M Series B, advancing therapies for inner ear disorders
Inner ear disorders, clinical-stage, platform technology, small molecule, rare disease - Read more

Helical raises $10M seed funding, virtual AI lab for pharma drug discovery
AI/ML platform, drug discovery, biomarker discovery, platform-enabled - Read more

Eli Lilly acquires CrossBridge Bio for up to $300M to advance dual-payload ADC cancer pipeline
Antibody-drug conjugate, oncology, strategic, major transaction - Read more

Obsidian Therapeutics goes public via reverse merger with Galera Therapeutics, raises $350M for TIL cancer therapies
Cell therapy, oncology, major transaction, financial - Read more

Amazon Web Services launches Amazon Bio Discovery AI tool to accelerate antibody design and drug discovery
Monoclonal antibody, oncology, AI drug discovery, operational - Read more

FDA contacts 2,200+ drug developers demanding public disclosure of clinical trial results amid transparency push
Regulatory, transparency, operational, financial - Read more

FDA issues draft safety guidelines for genome editing therapies to standardize off-target risk assessments
Gene therapy, rare disease, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Takeda terminates mRNA research collaboration with Veritas In Silico, upfront payment undisclosed
Research collaboration, small molecule, drug discovery, RNA targeting, milestone payments - Read more

Click Therapeutics cuts staff amid shift to commercial operations for digital therapeutic CT-155
Digital therapeutic, psychiatric/neurological, operational, cost reduction - Read more

Astellas closes Universal Cells' Seattle office, consolidating operations and impacting 50 employees
Cell therapy, oncology, strategic, operational, cost reduction - Read more

FDA requests additional Ph3 safety data on Eli Lilly's Foundayo (orforglipron) following GLP-1 agonist approval for weight loss
Small molecule, metabolic, GLP-1 agonist, obesity, type 2 diabetes, cardiovascular safety - Read more

FDA rebukes Pfizer for misleading Adcetris Facebook ads over inadequate indication and risk disclosure
Antibody-drug conjugate, oncology, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here